Skip to main content

Carmen Espejo Ruiz

I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Carmen Espejo Ruiz

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies.

I obtained my degree in Biology from the University of Barcelona in 1998. I did my doctoral thesis at the Clinical Neuroimmunology Unit of the Hospital Universitari Vall d'Hebron, in which I studied the role of metallothioneins in the pathogenesis of multiple sclerosis, obtaining my PhD in Biology from the University of Barcelona in 2005. In 2008, I got a Miguel Servet contract that allowed me to establish myself as principal investigator of the Clinical Neuroimmunology group – Multiple Sclerosis Centre of Catalonia. Currently, I am a senior researcher at the Vall d'Hebron Research Institute and develop my scientific activity in the Clinical Neuroimmunology group - Center d'Esclerosi Múltiple de Catalunya.
My main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim of developing new therapeutic strategies. I am currently focused on the role of immunosenescence in the pathogenesis of multiple sclerosis and the therapeutic potential of different senolytic drugs. I am also studying how the modification of the gut microbiota, through the administration of probiotics, could constitute a therapeutic tool in multiple sclerosis. Finally, I am carrying out a project that aims to induce immune tolerance, through the use of nanomedicine, with the aim of slowing down the autoimmune response in multiple sclerosis. I have more than 25 years of experience in animal models of multiple sclerosis and in the study of the immune response.
At the Vall d'Hebron Research Institute, I am a member (since 2003) and the president (since 2006) of the Animal Experimentation Ethics Committee. I am also part of the Biosafety Committee (since 2015) and the Research Integrity Committee (since 2020).
I have participated, as main or collaborating author, in 70 publications indexed in peer review journals. I have supervised eight doctoral theses and eight master's final projects. In addition, I participated as a teacher in various training activities, including the Master of Advanced Immunology at the Autonomous University of Barcelona and the University of Barcelona.

Projects

UNiC-Unitat de Neuroimmunologia Clínica

IP: Xavier Montalban Gairín
Collaborators: Carlos Nos Llopis, Jordi Rio Izquierdo, Manuel Comabella Lopez, Mar Tintore Subirana, M Jesus Arevalo Navines, Carmen Espejo Ruiz, Mireia Castillo Juarez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 35600
Reference: 2005SGR 01081
Duration: 01/01/2006 - 31/12/2008

Estudio de la subpoblación de linfocitos T CCR5+ en la etiopatogenia de la esclerosis múltiple (EM) y de la encefalomielitis autoinmune experimental (EAE).

IP: Xavier Montalban Gairín
Collaborators: Manuel Comabella Lopez, Carmen Espejo Ruiz
Funding agency: Instituto de Salud Carlos III
Funding: 47150
Reference: PI020160
Duration: 06/11/2002 - 06/11/2005

Inducción de tolerancia en la encefalitis autoinmune experimental mediante terapia génica

IP: Jordi Barquinero Mañez
Collaborators: Herena Eixarch Ahufinger, Carmen Espejo Ruiz
Funding agency: Instituto de Salud Carlos III
Funding: 71300
Reference: PI020205
Duration: 06/11/2002 - 06/11/2005

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Marc Martí Gallostra

Marc Martí Gallostra

Main researcher
General Surgery
Read more
Deborah Pareto Onghena

Deborah Pareto Onghena

Main researcher
Neuroradiology
Read more
Mª Dolores Braquehais Conesa

Mª Dolores Braquehais Conesa

Main researcher
Psychiatry, Mental Health and Addictions
Read more
Lucas Rivera Sánchez

Lucas Rivera Sánchez

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.